On September 21, HANSOH PHARMA rose 3.03% in regular trading, trading at HK$35.38/share, with turnover of approximately HK$55.87 million. The gain was driven by a significant clinical milestone announced earlier in the day.
HANSOH PHARMA disclosed that its self-developed selective allosteric TYK2 inhibitor HS-10374 achieved co-primary endpoints in a pivotal Phase III clinical trial for adult patients with moderate-to-severe plaque psoriasis. The trial also met multiple secondary endpoints, with over half of patients receiving HS-10374 achieving PASI 90 response at Week 16, and nearly one-third achieving complete skin clearance (PASI 100). Based on these results, the company plans to engage with regulators and advance new drug application preparations in China, with detailed data to be presented at an upcoming dermatology conference.
This milestone adds to a series of positive catalysts in recent weeks, including NMPA acceptance of the biologics license application for B7-H3 ADC HS-20093 in small cell lung cancer with priority review designation, and clinical trial approval for HS-20197 targeting advanced solid tumors. Multiple brokerages including Goldman Sachs, J.P. Morgan, and CLSA maintain bullish ratings with target prices ranging from HK$43.70 to HK$52.70.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments